(Q34272198)

1 August 2017

1 reference

title

Perspectives in hormone replacement therapy (English)

1 reference

1 August 2017

Kenemans P

1

1 reference

1 August 2017

van Unnik GA

series ordinal

2

1 reference

1 August 2017

Mijatovic V

series ordinal

3

1 reference

1 August 2017

van der Mooren MJ

series ordinal

4

1 reference

1 August 2017

publication date

1 June 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

38 Suppl 1

1 reference

1 August 2017

page(s)

S41-8

1 reference

Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Serum and tissue hormone levels of vaginally and orally administered estradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Postmenopausal hormone use and risk of large-bowel cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Estrogen replacement therapy and risk of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Postmenopausal hormone therapy and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Has the climacteric been medicalized? A study on the use of medication for climacteric complaints in four countries

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

A study on the use of medication for climacteric complaints in western Europe--II

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Use of hormone replacement therapy by postmenopausal women in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Compliance with hormonal replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

A population based survey of women's experience of the menopause.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Prevalence and determinants of estrogen replacement therapy in elderly women.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Utilisation of hormone replacement therapy by women doctors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Attitudes of obstetricians and gynecologists toward hormone replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Hormone therapy to prevent disease and prolong life in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Hormone replacement therapy, heart disease, and other considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared with nonusers

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Hormone replacement therapy: prevalence, compliance and the 'healthy women' notion

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

The heart and estrogen/progestin replacement study (HERS).

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

A critical European view of the HERS trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Postmenopausal hormone replacement therapy and cancer of the female genital tract and breast

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Endometrial response in estrogen replacement therapy quarterly combined with a progestogen

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Hormone replacement therapy and accuracy of mammographic screening

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900203-1

7 January 2021

10.1016/S0378-5122(01)00203-1

Identifiers

DOI

1 reference

1 August 2017

1 reference